-
Aminopeptidases and Brain Angiotensin Signaling
2026-09-25
Harding and Felix used iontophoretic pharmacology in rat brain neurons to test whether angiotensin II must be converted to angiotensin III before producing neuronal activity. Bestatin enhanced responses to both peptides, whereas amastatin selectively reduced angiotensin II responses, supporting a role for aminopeptidase-dependent peptide processing while leaving important mechanistic questions open.
-
GANT61 in ALK-Positive ALCL: Apoptosis and Signaling
2026-09-25
The 2026 study reports that the Gli-targeting compound GANT61 reduces proliferation and promotes cell-cycle arrest and apoptosis in ALK-positive anaplastic large cell lymphoma (ALK+ ALCL) cell lines. Its findings connect Gli1 inhibition with increased PIK3IP1 expression and reduced Akt phosphorylation, identifying the Hh–PIK3IP1–Akt axis as a candidate mechanism that warrants further causal and translational testing.
-
CSBTA Pharmacokinetics in MASH Model Mice
2026-09-24
This study integrates plasma, tissue, and cellular pharmacokinetic measurements to show that HFHCD-induced MASH alters the disposition of key Corydalis saxicola Bunting total alkaloids. Its findings connect disease-associated changes in exposure and liver accumulation with CYP450 enzymes, Oatp1b2, P-glycoprotein, and PXR, highlighting why disease state and repeat dosing matter when interpreting preclinical drug exposure.
-
Capsaicin-Driven Autophagy Protects BMSCs Under Stress
2026-09-24
A study in rat bone marrow stromal cells (BMSCs) reports that capsaicin improves cell viability and osteogenic readouts during hydrogen peroxide-induced oxidative stress. The authors propose a mechanism involving TRPV1-associated calcium influx, increased autophagy, and reduced PI3K/AKT/mTOR phosphorylation, while noting a potential relevance to osteoporosis research.
-
Decitabine and Immune Tolerance: Lessons from ITP
2026-09-23
Decitabine (5-Aza-2'-deoxycytidine) can influence immune-cell behavior as well as DNA methylation. This article examines a study in immune thrombocytopenia and translates its findings into practical assay-design decisions—with clear boundaries on what the evidence does and does not establish.
-
Gramine: From Target Engagement to Ferroptosis Proof
2026-09-23
Gramine is a mechanistically informative ferroptosis inducer for cancer biology research. This guide translates CUL3–MTDH findings into an evidence-weighted assay strategy for triple-negative breast cancer research, emphasizing target engagement, causal controls, and compound handling.
-
OSMI-1: O-GlcNAc Transferase Inhibitor Guide
2026-09-22
OSMI-1 is a cell-permeable O-GlcNAc transferase inhibitor with a reported IC50 of 2.7 μM. It reduces cellular O-GlcNAcylation and provides a chemical tool for O-GlcNAcylation research, but its cytotoxicity and the opposing direction of recent preeclampsia findings require controlled interpretation.
-
HOXC8, Caspase-1, and Pyroptosis in Lung Cancer
2026-09-22
A 2025 Cell Death and Disease study identifies HOXC8 as a transcriptional suppressor of CASP1 in non-small cell lung cancer. Its depletion derepresses caspase-1, triggers ASC-independent pyroptosis, and provides a mechanistic link between transcriptional regulation and tumor-cell vulnerability.
-
Phillygenin in Diabetic Nephropathy: Pathway Evidence
2026-09-21
The reference study identifies phillygenin as a candidate intervention for diabetic nephropathy and connects its protective effects with suppression of TLR4/MyD88/NF-κB inflammation and restoration of PI3K/AKT/GSK3β signaling. Its combined cell, transcriptomic, biochemical, and mouse-model design provides a useful framework for studying podocyte injury, inflammation, and apoptosis, while still requiring validation beyond db/db mice.
-
Esflurbiprofen and SERT–nNOS Signaling
2026-09-21
The reference study identifies esflurbiprofen as a candidate fast-onset antidepressant by disrupting the SERT–nNOS complex in the dorsal raphe nucleus. Its screening, behavioral, neuroimaging, and mechanistic experiments suggest that altering transporter-associated signaling can reduce 5-HT1A autoreceptor feedback and restore serotonergic output in stressed mice.
-
Protease Inhibitor Cocktail for DFCP1–ATGL Lysates
2026-09-20
Preserve labile DFCP1–ATGL interactions and lipid-droplet proteins during extraction with a broad-spectrum, EDTA-containing formulation. The workflow combines practical cold-chain handling with assay-specific safeguards for Western blotting, Co-IP, imaging, and kinase studies.
-
Gramine, CUL3–MTDH, and Ferroptosis in TNBC
2026-09-19
A 2026 study identifies Gramine as a mechanistically defined ferroptosis inducer in triple-negative breast cancer through disruption of the CUL3–MTDH ubiquitination axis. Its combination of target-engagement assays, ferroptosis rescue experiments, genetic perturbation, and mouse models provides a useful framework for studying how MTDH stabilization can drive oxidative cancer-cell death.
-
MLN2238: Proteasome β5 Inhibition
2026-09-18
MLN2238 is a reversible proteasome β5 subunit inhibitor with nanomolar biochemical potency and broader proteasome-site inhibition at higher concentrations. Research findings connect MLN2238-mediated proteasome stress with ROS–JNK–CREB signaling, while product data support applications in multiple myeloma and lymphoma research.
-
Protein A/G Magnetic Co-IP/IP Kit for RNF8
2026-09-18
Use the Protein A/G Magnetic Co-IP/IP Kit to test native RNF8–DAPK1 complexes in ischemic-stroke models with rapid magnetic handling and clear controls. The workflow also supports antibody purification using magnetic beads and orthogonal validation of exosome-driven signaling mechanisms.
-
T-5224: Mapping AP-1 to Inflammation and Ferroptosis
2026-09-17
T-5224, a selective C-Fos/AP-1 inhibitor, offers a way to connect transcription-factor activity with inflammatory, osteoclastogenic, and ferroptotic phenotypes. This article presents a decision framework for choosing assays, interpreting pathway rescue, and separating established evidence from translational hypotheses.